You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.
2021 is off to a fantastic start for cannabis investors. We will be detailing the performance shortly, but the New Cannabis Ventures Global Cannabis Stock Index tacked on a 27.8% gain in January on top of the Q4 rise of nearly 62%. Since the end of September, the index has more than doubled.
Four weeks ago, we discussed why we expected the growth to continue, sharing 9 potential growth drivers, and some of these are already kicking in, especially on two fronts: improving access to capital and a heightened pace of M&A.
During January, seven of the largest American multi-state operators (MSOs) by market cap raised equity capital that we would consider for growth. The deals got done at relatively tight discounts to the market price, typically without warrants, and were supported by substantial institutional investor participation. Beyond the equity markets, Curaleaf priced a $50 million debt deal that suggests improving terms for borrowing.
The table below shows the amount of capital raised by each company:
Capital raising wasn’t limited to MSOs, as we saw several Canadian licensed producers (LPs) sell shares. These deals were less about growth capital than balance sheet repair for the most part, but some of the capital raises, like Village Farms, were for growth.
M&A has been taking place in both Canada and the U.S. We first shared our expectation that consolidation would be a big theme in mid-December, right before Ayr Strategies announced two single-state operator buys and Columbia Care announced the pending acquisition of private MSO Green Leaf Medical. Since then, Columbia Care announced another California acquisition, while Cresco Labs announced the pending acquisition of Florida operator Bluma Wellness. In Canada, Israeli operator IM Cannabis announced the pending acquisition of Trichome Financial, Heritage Cannabis bought a private LP, Valens announced it is acquiring a private LP, and Alcanna, as part of a spin-out of its retail cannabis operations, will be acquiring another retailer, YSS.
Another early theme has been very high trading volumes, especially for names that trade on higher exchanges. For the MSOs, we believe that the scaling up of AdvisorShares Pure US Cannabis ETF as well as increasing institutional demand has helped boost trading volumes, and these higher volumes have made it easier for companies to raise capital or insiders and early investors to sell stock without disrupting the price significantly.
Looking ahead, we expect that a lot of the M&A will likely be consolidation of private single-state operators or small MSOs, so it’s not clear that there are obvious public company acquisition targets in the U.S, but we think that we might see some consolidation in Canada that could include public company combinations. We believe that Curaleaf is a very likely consolidator, and we have shared that we expect it to make an acquisition in California
As we mentioned, seven of the largest MSOs have raised capital for growth, and the other three might do so as well. We note that after filing its initial S-1 to sell up to 10 million shares in August, GTI amended it on January 19th, perhaps a signal that it could be issuing equity. On Friday evening, Trulieve disclosed that it has filed a $750 million shelf registration. Harvest Health and Recreation also has an open shelf. Of course, smaller MSOs may raise equity capital as well. We continue to expect equity offerings in the U.S. to be well absorbed. This suggests that investors should be prepared to “buy the dip” on equity offerings, a strategy that can work due to the bull market that cannabis stocks are in now.
2021 began with a sharp spike in stocks in the first two weeks, triggered by the change of control of the Senate. While the back half of the month saw a modest pullback, the market looks very healthy from our vantage. With corporate coffers topped off after this recent round of capital raising, we expect the pace of M&A to accelerate in the months ahead.
Why Investors Subscribe:
Real-time, market moving news and analysis! Cut out the noise and get the facts straight from the longest running full-time cannabis analyst.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$12.5M per quarter.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Alan & Joel